04:32 PM EDT, 03/09/2026 (MT Newswires) -- Design Therapeutics ( DSGN ) reported Q4 net loss late Monday of $0.27 per diluted share, wider than a loss of $0.24 a year earlier.

Analysts polled by FactSet expected a loss of $0.35.

The company reports cash, cash equivalents and investment securities of $219.8 million as of Dec. 31, which the company expects to fund its planned operations into 2029.